The asset sale portion of Emergent BioSolutions’ sweeping restructuring plan is taking shape.

Emergent BioSolutions全面重组计划的资产出售部分正在形成。

In a $30 million deal, Emergent has agreed to sell its fill-finish drug product facility in Baltimore to growing Taiwanese CDMO Bora Pharmaceuticals, the two companies said Thursday.

两家公司周四表示，在一项3000万美元的交易中，Emergent同意将其在巴尔的摩的fill finish药品工厂出售给成长中的台湾CDMO Bora制药公司。

The 87,000-square-feet Camden facility offers clinical and commercial non-viral aseptic fill-finish services on four fill lines, including lyophilization, formulation development and support services.

87000平方英尺的卡姆登工厂在四条灌装线上提供临床和商业非病毒无菌灌装服务，包括冻干、配方开发和支持服务。

About 350 Emergent employees are expected to join Bora as part of the transaction, which is expected to close in the third quarter of 2024, according to Emergent. Bora, through a media aide, confirmed to Fierce Pharma via email that the company plans to keep all existing employees at the plant.

据Emergent称，作为交易的一部分，预计约350名Emergent员工将加入宝来，交易预计将于2024年第三季度完成。。

“The decision to sell our Camden manufacturing facility is aligned with our multi-year plan to create a customer focused, leaner and more flexible organization, while we improve overall profitability and raise capital to reduce our debt,” newly minted Emergent CEO Joe Papa said in a statement Thursday..

“出售卡姆登制造厂的决定符合我们的多年计划，即创建一个以客户为中心、更精简、更灵活的组织，同时我们提高整体盈利能力并筹集资金以减少债务，”新任紧急CEO乔·帕帕在周四的一份声明中表示。。

The Camden site doesn’t have the most pristine track record. Following an FDA Form 483, the plant was slapped with an FDA warning letter in 2022 that detailed problems related to equipment cleaning, aseptic sterilization techniques and procedures, and quality systems. The problems were deemed adequately addressed and the warning letter closed following another FDA inspection last summer..

卡姆登网站没有最原始的记录。根据FDA 483表格，该工厂于2022年收到FDA警告信，详细说明了与设备清洁、无菌灭菌技术和程序以及质量体系有关的问题。这些问题被认为得到了充分解决，警告信在去年夏天FDA再次检查后关闭。。

The sale represents one piece in Emergent’s plan to deprioritize its CDMO business. About two months into his CEO role, Papa in May unveiled a restructuring initiative to reduce the company’s workforce by about 300 employees and to shut down two manufacturing facilities, while exploring strategic alternatives for some other plants..

此次出售代表了Emergent解除CDMO业务优先级计划的一部分。在担任首席执行官大约两个月后，爸爸于5月推出了一项重组计划，旨在减少公司约300名员工，关闭两家制造厂，同时探索其他一些工厂的战略替代方案。。

Related

相关

Emergent BioSolutions to cut 300 employees, shutter 2 facilities in restructuring launched under new CEO

紧急生物解决方案将裁减300名员工，在新任首席执行官的领导下，关闭2家重组工厂

The two facilities being closed are located in Baltimore-Bayview and Rockville, Maryland. The Camden facility belongs to the group of sites for which Emergent has been weighing its options.

被关闭的两个设施位于马里兰州巴尔的摩湾景城和罗克维尔。Camden设施属于Emergent一直在权衡其选择的场地组。

Besides sites in Winnipeg, Canada, and Lansing, Michigan, which Emergent said it will keep, the company also owns about 122,500 square feet of manufacturing and warehouse space in Canton, Massachusetts, where Emergent has scaled back operations.

除了位于加拿大温尼伯和密歇根州兰辛的工厂外，Emergent表示将保留这些工厂，该公司还在马萨诸塞州坎顿拥有约122500平方英尺的制造和仓库空间，Emergent在那里缩减了运营。

In contrast to Emergent’s shrinking interest in the CDMO field, Bora has been on an expansion spree. The Taiwanese company just established a U.S. footprint earlier this year with a $210 million acquisition of Minnesota generics manufacturer Upsher-Smith Laboratories.

与Emergent在CDMO领域的兴趣萎缩相反，Bora一直在疯狂扩张。这家台湾公司今年早些时候以2.1亿美元收购了明尼苏达州仿制药制造商Upsher Smith Laboratories，在美国建立了业务。

The Upsher-Smith buy followed two acquisitions by Bora in 2022. Through the purchase of fellow Taiwanese company TWi Pharmaceuticals, Bora gained two manufacturing facilities and some niche technologies. The same year, Bora beefed up its biologics capabilities by acquiring Eden Biologic’s CDMO business..

Upsher Smith收购案发生在宝来于2022年进行两次收购之后。通过收购台湾同行TWi制药公司，宝来获得了两个生产设施和一些利基技术。。。

Related

相关

Bora plants its flag in the US with $210M acquisition of generics manufacturer Upsher-Smith

宝来以2.1亿美元收购仿制药制造商Upsher Smith，将旗插在美国

Buying the Camden sterile injectable fill-finish plant “not only demonstrates our commitment to our growth strategy and plans for expansion in North America, but also enables us to expand our offering for our biologics customers,” Bora CEO Bobby Sheng said in a statement Thursday.

博拉首席执行官鲍比·盛（BobbySheng）周四在一份声明中表示，购买卡姆登（Camden）无菌注射灌装厂“不仅表明了我们对北美增长战略和扩张计划的承诺，而且使我们能够扩大为生物制品客户提供的产品。”。

Without offering further details, Bora said it has “ambitious plans to enhance the newly acquired facility.” And the company is “always considering sites that are available,” Bora told Fierce Pharma.

在没有提供更多细节的情况下，宝来表示，它“有雄心勃勃的计划来加强新收购的设施。”宝来对威猛制药表示，该公司“一直在考虑可用的网站”。

“We are planning to expand our operations across the US market to significantly enhance Bora’s position as a global competitor,” the company said. “As part of our growth strategy, we are constantly listening to our customer's needs to spot opportunities to provide the best possible service.”

该公司表示：“我们计划在美国市场拓展业务，以显著提升宝来作为全球竞争对手的地位。”。“作为我们增长战略的一部分，我们不断倾听客户的需求，以发现提供最佳服务的机会。”